Methods for treating pain by administering a nerve growth factor antagonist and an NSAID

• US 7,655,231 B2
• Filed: 02/19/2004
• Issued: 02/02/2010
• Est. Priority Date: 02/19/2003
• Status: Expired due to Fees

• Current Assignee: Rinat Neuroscience Corp. (Pfizer Inc.)
• Original Assignee: Pfizer Inc.
• Inventors: Vergara, German J., Shelton, David L., Loo, Carole M.
• Primary Examiner(s): Saoud; Christine J
• Assistant Examiner(s): Lockard; Jon M
• Application Number:
  US10/783,730
• Publication Number:
  US 20040253244A1
• Time in Patent Office: 2,175 Days
• Field of Search: None
• US Class Current: 424/145.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention features methods for treating or preventing pain comprising administering an amount of a nerve growth factor antagonist (such as an anti-NGF antibody) and an amount of an NSAID such that together they provide effective pain relief. The invention also features compositions comprising a nerve growth factor antagonist and an NSAID and kits containing the same.

Claims

1. A method for treating pain in an individual comprising administering to the individual an effective amount of an anti-nerve growth factor (NGF) antibody and an NSAID, whereby the anti-NGF antibody and the NSAID in conjunction provide effective pain relief, wherein the anti-NGF antibody comprises the heavy chain variable region shown in SEQ ID NO:

1 and the light chain variable region shown in SEQ ID NO;

2.

2. The method of claim 1, wherein the NSAID is selected from the group consisting of ibuprofen, naproxen, naprosyn, diclofenac, ketoprofen, tolmetin, sulindac, mefanamic acid, meclofenamic acid, diflunisal, flufenisal, piroxicam, sudoxicam, isoxicam, celecoxib, fofecoxib, DUP-697, flosulide, meloxicam, 6-methoxy-2-naphthylacetic acid, MK-966, nabumetone, nimesulide,NS-398, SC-5766, SC-58215, and T-614.

3. The method of claim 1, wherein the NSAID is ibuprofen.

4. The method of claim 1, wherein the pain is post-surgical pain.

5. The method of claim 1, wherein the anti-NGF antibody and the NSAID in conjunction provide a greater effect in treating pain than the corresponding amount of NSAID alone.

6. The method of claim 1, wherein the individual is a human.

7. The method of claim 1, 2, or 3, wherein the anti-NGF antibody binds human NGF.

8. The method of claim 7, wherein the anti-NGF antibody binds human NGF with a binding affinity of about 10 nM or less than about 10 nM.

9. The method of claim 7, wherein the pain is post-surgical pain.

10. The method of claim 1, wherein the anti-NGF antibody is a monoclonal antibody.

11. The method of claim 10, wherein the monoclonal antibody is a humanized antibody, a human antibody, a chimeric antibody, a bispecific antibody or an antibody fragment, wherein the antibody fragment is Fab, Fab′

, (F9ab′

)2, Fv fragments, diabodies, single chain antibody molecules, multispecific antibodies, or a single-chain Fv molecule.

12. The method of claim 10, wherein the monoclonal antibody is E3.

13. A pharmaceutical composition for treating pain comprising an effective amount of an anti-nerve growth factor (NGF) antibody and an NSAID, whereby the anti-NGF antibody and the NSAID in conjunction provide effective pain relief, wherein the anti-NGF antibody comprises the heavy chain variable region shown in SEQ ID NO:

1 and the light chain variable region shown in SEQ ID NO;

2 , and a pharmaceutically acceptable carrier.

14. The pharmaceutical composition of claim 13, wherein the anti-NGF antibody and the NSAID are in the same composition or separate compositions.

15. A kit for treating pain comprising an anti-nerve growth factor (NGF) antibody and an NSAID, whereby the anti-NGF antibody and the NSAID in conjunction provide effective pain relief, wherein the anti-NGF antibody comprises the heavy chain variable region shown in SEQ ID NO:

1 and the light chain variable region shown in SEQ ID NO;

2, and instructions for administering the anti-NGF antibody in conjunction with the NSAID to treat pain.

16. The kit of claim 15, wherein the anti-NGF antibody is a monoclonal antibody.

17. The kit of claim 16, wherein the monoclonal antibody is a humanized antibody, a human antibody, a chimeric antibody, a bispecific antibody or an antibody fragment, wherein the antibody fragment is Fab, Fab′

, (F9ab′

)2, Fv fragments, diabodies, single chain antibody molecules, multispecific antibodies, or a single-chain Fv molecule.